Pseudomonas aeruginosa. This is, in fact, the point we hoped to make. However, they go on to suggest that these relatively low concentrations of ertapenem will be ineffective against this strain. It is with this issue that we are concerned. In our article, we indicate that the emergence and spread of resistance are greatly enhanced at subinhibitory concentrations; however, resistance emergence is also a dynamic process of the progressive concentration of resistant strains within the clinical population, often by the same or related strains. In the individual case that Brink et al.
*Tel: þ1-718-270-3097; Fax: þ1-718-270-1985; E-mail: mhammerschlag@downstate.edu Sir, Assessing the microbiological efficacy of antibiotic treatment against respiratory infections caused by atypical organisms, specifically Chlamydia pneumoniae and Mycoplasma pneumoniae, is difficult. Culturing is difficult and not readily available. There are no validated, commercially available nucleic acid amplification tests for either organism. 1 Recently, File et al.
2
reported a study comparing 5 day versus 7 day treatment of community-acquired pneumonia with gemifloxacin. They used serology alone to determine whether patients were infected with C. pneumoniae and M. pneumoniae. The authors state in the Methods section that 'because only serology was used for identification, bacteriological outcome was presumed on the basis of clinical response'. However, under 'bacteriologic outcomes', they state that C. pneumoniae and M. pneumoniae were 'identified' and refer to 'eradication' of these organisms in Table 3 . Unfortunately, serology, especially for C. pneumoniae, is not standardized and correlates poorly with identification of the organism by culture or validated PCR. 1 As many as 40% to 70% of patients with culture-documented C. pneumoniae infection will remain seronegative.
1 Serology does not detect or identify an organism; it indicates possible exposure. We have previously demonstrated in two studies of community-acquired pneumonia in adults, utilizing cultures, that treatment with levofloxacin or moxifloxacin eradicated C. pneumoniae from 80% and 70% of infected patients, respectively. 3, 4 We also demonstrated poor correlation between serology, using the microimmunofluorescence assay, and culture. However, the patients who were microbiological failures were clinical cures, despite persistence of the organism. In vitro activity does predict in vivo efficacy. The MICs of moxifloxacin and gemifloxacin for C. pneumoniae are very similar. 5 Use of serology, at best, only allows a clinical endpoint. We need a consistent policy on acceptable criteria for determining microbiological efficacy for C. pneumoniae and M. pneumoniae infection.
Transparency declarations
None to declare. Sir, We are in agreement with Dr Hammerschlag 1 that assessment for Chlamydophila pneumoniae as an aetiology of respiratory infections is difficult; and we share her call for a consistent regulatory policy on acceptable criteria for determining microbiological efficacy. Since serological methods were the only means by which an atypical aetiology was assessed in our paper, we acknowledge this as a potential limitation, but felt that we should include this information to give the reader some impression of the pattern of aetiological agents found in our cases.
We would like to stress that the primary purpose of our paper was to demonstrate the clinical efficacy of a shorter 5 day course of gemifloxacin therapy for mild-to-moderate community-acquired pneumonia with the possible benefits which may accrue. We feel that we have demonstrated this in our paper. Sir, In a recent study on transferable quinolone resistance among Salmonella enterica strains isolated in the UK, qnrS1 genes were identified on plasmids in the four serotypes Typhimurium, Stanley, Virchow and Virginia. 1 Since no complete sequence of a qnrS1-carrying plasmid has been available so far, we decided to sequence completely the smallest type of qnrS1-carrying plasmid to gain insight into the structure and putative origin of this plasmid. The plasmid chosen, TPqnrS-1a, was obtained from a multiresistant Salmonella Typhimurium DT193 strain and previously shown to mediate only decreased susceptibility to ciprofloxacin. 
